Skip to content

Isoflurane-induced Neuroinflammation in Children With Hydrocephalus

Isoflurane-induced Neuroinflammation in Children With Hydrocephalus: A Bench-to-bedside, Translational Study of Molecular Pathways and Therapeutic Approaches

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02512809
Enrollment
25
Registered
2015-07-31
Start date
2015-07-31
Completion date
2017-10-31
Last updated
2018-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydrocephalus, Toxicity

Brief summary

The investigators will quantify inflammatory biomarkers in cerebrospinal fluid (CSF) and serum of children with hydrocephalus who are undergoing ventriculoperitoneal shunt placement under isoflurane anesthesia.

Detailed description

Background & Significance. Each year, millions of children receive general anesthesia. Isoflurane, a GABA type A (GABAA) receptor agonist is an inhaled anesthetic commonly used in clinical anesthesia practice worldwide. Anesthetics traditionally have been assumed to be safe as long as severe hypotension and hypoxia are avoided. Interfering with the balance of excitatory and inhibitory neurotransmitters in the developing brain may interfere with the formation of synaptic connections and enhance the normal apoptotic processes that lead to neuronal pruning and may induce neuroinflammation. Such enhanced neuronal pruning and neuroinflammation could lead to excessive neuronal loss at critical times during brain development and consequently cause later learning disabilities. Recent reports of neurotoxicity induced with isoflurane have triggered significant concern about the safety of this agent. Investigations into neuroinflammation and apoptosis after anesthetic exposure in human children have been limited due to ethical and methodological concerns. Studies that have been done have been largely retrospective, population-based studies. Results from these studies have been mixed, some showing a decline in neurocognitive performance, some showing no change. Further, the vast majority of prospective, hypothesis-driven research has been undertaken in animal models. Developing a clinically relevant animal model and testing resultant hypotheses in humans are critical steps in determining the underlying cause of these changes as well as identifying possible therapeutic targets. The investigators hypothesize that piglets exposed to commonly used anesthetics will exhibit increased neuroinflammation when compared with controls. It is further hypothesized children undergoing neurosurgery with isoflurane anesthesia will show evidence of increased central nervous system inflammation. Finally, the investigators hypothesize that significantly less robust inflammation will be seen in patients undergoing MRI with general anesthesia (no surgery), indicating a role of surgical stress in the modulation of isoflurane-induced neuroinflammation. Clinical/Translational Investigation (NCH): Surgery Group. Patients aged 0-5 years undergoing general anesthesia for ventriculoperitoneal shunt (VPS) repair will have CSF and serum sampled at the beginning of surgery (after induction but before surgical incision) and at the end of surgery (after closure but before emergence). Each of these patients will be randomized to a standardized anesthetic. An additional CSF sample will be taken prior to post anesthesia care unit (PACU) discharge. These samples will be analyzed as described above. Control Group. Patients undergoing diagnostic MRI under general anesthesia for non-neurologic pathology will receive a standardized anesthetic. Serum will be collected at the beginning and end of the procedure and will be analyzed for inflammation as above. Short term goals: Demonstrate that isoflurane has a role in modulation of neuroinflammation in humans. Determine if surgical stress also has a role in modulation of this inflammation. Develop a clinically relevant animal model for hypothesis-driven anesthetic neuroinflammation research. Long term goals: Identify which anesthetic regimens, if any, are safe for use in the developing brain. Identify therapeutic targets for prevention or treatment of anesthetic-induced neuroinflammation. Obtain independent federal funding for future research and establish an experimental neuroscience program on the Nationwide Children's campus.

Interventions

DRUGIsoflurane
DRUGDexmedetomidine

Sponsors

Ohio State University
CollaboratorOTHER
Nationwide Children's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 5 Years
Healthy volunteers
No

Inclusion criteria

(HC study patients): * Pediatric patients, aged 6 months-less than 11 years, diagnosed with hydrocephalus undergoing a primary surgical (non-bedside) shunting procedure with general anesthesia. * Participants must have a parent/guardian who is able to provide written informed consent in accordance with human investigation committee guidelines. * The shunting procedure must be an initial VPS placement (not a VPS revision). Inclusion Criteria (MRI with general anesthesia: peripheral blood patients; anesthesia but no surgery): * Otherwise healthy pediatric patients, aged 6 months-less than 11 years, undergoing MRI with general anesthesia for evaluation of non-neurologic, non-inflammatory disease. * Participants must have a parent/guardian who is able to provide written informed consent in accordance with IRB guidelines.

Exclusion criteria

(HC study patients): * Any active infection or infection within the last 14 days. * Treatment in the last 48 hours with non-steroidal anti-inflammatory (NSAID) or corticosteroid medications. * Anticoagulant administration in the last 48 hours. * Treatment with any drug known to induce or suppress inflammation. * Clinically unstable patients. * Patients that have an American Society of Anesthesiologists physical status ≥4 (severe, life-threatening disease). * Infants born more than 4 weeks premature.

Design outcomes

Primary

MeasureTime frameDescription
Change in Serum Cytokine LevelsOn the day of surgery or MRI from start of procedure to discharge from PACU (approx. 1-7 hrs.)Surgery subjects will have blood collected once at the start of surgery, once at the end of surgery, and once in the PACU. MRI patients will have blood collected once prior to the start of the MRI and once at the completion of the MRI.

Participant flow

Pre-assignment details

There were no participants assigned to the Isoflurane and Dexmedetomidine/Remifentanil Arm Arms/Groups as only the MRI control arm completed enrollment prior to the original PI leaving the institution and there was no enrollment in the other 2 arms.

Participants by arm

ArmCount
Isoflurane Arm
Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane. Isoflurane
0
Dexmedetomidine/Remifentanil Arm
Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions.. Dexmedetomidine
0
MRI Control Arm
Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
25
Total25

Baseline characteristics

CharacteristicIsoflurane ArmDexmedetomidine/Remifentanil ArmMRI Control ArmTotal
Age, Categorical
<=18 years
0 Participants0 Participants25 Participants25 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants0 Participants
Age, Continuous3.73 years
STANDARD_DEVIATION 2.49
3.73 years
STANDARD_DEVIATION 2.49
American Society of Anesthesiologists (ASA) Physical Status classification
ASA 1
8 Participants8 Participants
American Society of Anesthesiologists (ASA) Physical Status classification
ASA 2
17 Participants17 Participants
Anesthetic Time54.7 minutes
STANDARD_DEVIATION 24.7
54.7 minutes
STANDARD_DEVIATION 24.7
Previous Anesthesia
No
13 Participants13 Participants
Previous Anesthesia
Yes
12 Participants12 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants3 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants
Race (NIH/OMB)
White
21 Participants21 Participants
Sex: Female, Male
Female
10 Participants10 Participants
Sex: Female, Male
Male
15 Participants15 Participants
Weight17.4 kilograms
STANDARD_DEVIATION 8.3
17.4 kilograms
STANDARD_DEVIATION 8.3

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 25
other
Total, other adverse events
0 / 25
serious
Total, serious adverse events
0 / 25

Outcome results

Primary

Change in Serum Cytokine Levels

Surgery subjects will have blood collected once at the start of surgery, once at the end of surgery, and once in the PACU. MRI patients will have blood collected once prior to the start of the MRI and once at the completion of the MRI.

Time frame: On the day of surgery or MRI from start of procedure to discharge from PACU (approx. 1-7 hrs.)

ArmMeasureGroupValue (MEAN)Dispersion
MRI Control ArmChange in Serum Cytokine LevelsIL-1β pre-isoflurane25.97 pg/mlStandard Deviation 9.01
MRI Control ArmChange in Serum Cytokine LevelsIL-1β post-isoflurane38.53 pg/mlStandard Deviation 16.56
MRI Control ArmChange in Serum Cytokine LevelsTNF-α pre-isoflurane94.26 pg/mlStandard Deviation 18.07
MRI Control ArmChange in Serum Cytokine LevelsTNF-α post-isoflurane85.84 pg/mlStandard Deviation 12.12
MRI Control ArmChange in Serum Cytokine LevelsIL-6 pre-isoflurane2.28 pg/mlStandard Deviation 2.27
MRI Control ArmChange in Serum Cytokine LevelsIL-6 post-isoflurane2.04 pg/mlStandard Deviation 2.15

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026